Canigen DHP
Active substance
ATC code
Species
Dogs.
Indications
For the active immunisation of dogs to reduce clinical signs of disease caused by canine distemper virus infection; to prevent clinical signs and viral excretion caused by canine parvovirus infection; to reduce clinical signs of canine contagious hepatitis and viral excretion due to canine adenovirus 1 infection and to reduce clinical signs of respiratory infection and viral excretion caused by adenovirus type 2 infection.
Onset of immunity: one week.
Duration of immunity: three years.
Dose to be administered and administration route
Subcutaneous use.
Reconstitute immediately prior to use by the addition of the contents of one vial (1.0 ml) of the diluent provided or the vaccines of the Canigen range against rabies or leptospirosis as mentioned in section 4.8 (where these products are authorised). Sterile equipment should be used for administration.
Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.
Vaccination regime
Primary course vaccination:
A single injection should establish active immunity in dogs of 10 weeks of age or older. Where earlier protection is required a first dose may be given to puppies from 6 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination a final dose should be given 2 - 4 weeks later i.e. at 10 weeks of age or older.
Booster vaccination:
To maintain protection a single booster dose is recommended every three years.
Adverse reactions
A common reaction after subcutaneous administration with the diluent provided is a diffuse swelling up to 5 mm in diameter at the site of injection. Occasionally this swelling may be hard and painful and last for up to 3 days post injection.
In rare cases a transient rise in body temperature and/or a transient acute hypersensitivity reaction (anaphylaxis) - with signs that may include lethargy, facial oedema, pruritus, dyspnoea, vomiting, diarrhoea or collapse - may occur shortly after vaccination.
Clinical signs of immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia or immune-mediated polyarthritis have been reported in very rare cases
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports)
Dispensing
POM-V - Prescription Only Medicine – Veterinarian
TRUSTED SOURCE
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Canigen DHP lyophilisate and solvent for suspension for injection.
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml dose of reconstituted vaccine contains: Active substances:
|
Canine distemper virus, strain Onderstepoort |
≥ 104.0 TCID50* |
|
Canine adenovirus 2, strain Manhattan LPV3 |
≥ 104.0 TCID50* |
|
Canine parvovirus, strain 154 |
≥ 107.0 TCID50* |
*Tissue culture infective dose 50%
Solvent (1 ml per vial):
Phosphate buffered saline.
Excipients:
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Lyophilisate and solvent for suspension for injection.
4. CLINICAL PARTICULARS
4.1 Target species
Dogs.
4.2 Indications for use, specifying target species
For the active immunisation of dogs to reduce clinical signs of disease caused by canine distemper virus infection; to prevent clinical signs and viral excretion caused by canine parvovirus infection; to reduce clinical signs of canine contagious hepatitis and viral excretion due to canine adenovirus 1 infection and to reduce clinical signs of respiratory infection and viral excretion caused by adenovirus type 2 infection.
Onset of immunity: one week.
Duration of immunity: three years.
4.3 Contraindications
None.
4.4 Special warnings for each target species
The efficacy of the CDV, CAV2 and CPV components of the vaccine may be reduced due to maternal antibody interference. However, the vaccine has been proved to be of benefit against virulent challenge in the presence of maternal antibody levels to CDV, CAV2 and CPV that are likely to be encountered under field conditions.
4.5 Special precautions for use
Special precautions for use in animals:
Only healthy dogs should be vaccinated. Dogs should not be exposed to unnecessary risk of infection within the first 2 weeks after completion of the vaccination regimen.
While the canine parvovirus vaccine strain may be shed at very low levels for up to 8 days after inoculation, there is no evidence that this results in clinical symptoms if nonvaccinated animals are infected.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In the case of accidental self-injection, wash the area immediately with water. If symptoms develop, seek medical attention showing a copy of package leaflet.
4.6 Adverse reactions (frequency and seriousness)
A common reaction after subcutaneous administration with the diluent provided is a diffuse swelling up to 5 mm in diameter at the site of injection. Occasionally this swelling may be hard and painful and last for up to 3 days post injection.
In rare cases a transient rise in body temperature and/or a transient acute hypersensitivity reaction (anaphylaxis) - with signs that may include lethargy, facial oedema, pruritus, dyspnoea, vomiting, diarrhoea or collapse - may occur shortly after vaccination.
Clinical signs of immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia or immune-mediated polyarthritis have been reported in very rare cases
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports)
4.7 Use during pregnancy and lactation
Can be used in pregnant bitches which have previously been vaccinated with the Canigen DHPPi, DHP, Parvo-C or Pi.
4.8 Interactions with other medicinal products and other forms of interaction
Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with the inactivated vaccines of the Canigen range against canine leptospirosis caused by all or some of the following serovars: L. interrogans serogroup Canicola serovar Canicola, L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar Bratislava, and L. kirschneri serogroup Grippotyphosa serovar Bananal/Liangguang.
After administration with one of the leptospirosis vaccines, a mild and transient increase in body temperature (≤ 1 °C) may occur for a few days after vaccination, with some pups showing less activity and/or a reduced appetite. A small transient swelling (≤ 4 cm), which can occasionally be firm and painful on palpation, may be observed at the site of injection. Any such swelling will either have disappeared or be clearly diminished by 14 days postvaccination.
After mixed administration of an overdose of Canigen DHP and an overdose of the leptospirosis vaccines of the Canigen range, transient local reactions such as diffuse to firm swellings from 1 to 5 cm in diameter may be observed, usually these will persist no longer than 5 weeks, however some may take a little longer to completely disappear.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with the inactivated vaccine of the Canigen range against rabies. After administration with the rabies vaccine, where this product is authorised, transient local reactions such as diffuse to firm swellings from 1 to 4 cm in diameter may be observed for up to 3 weeks after vaccination. The swellings may be painful for up to 3 days post dosing.
Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day, but not mixed, with the live vaccine for intranasal administration of the Canigen range against infectious tracheobronchitis caused by Bordetella bronchiseptica and/or canine parainfluenza virus.
Safety and efficacy data are available which demonstrate that this vaccine can be administered at the same time but not mixed with the inactivated vaccine of the Canigen range against Bordetella bronchiseptica.
When Canigen DHP is used with any of the other Canigen vaccines referred to above, the minimum vaccination age for each vaccine must be taken into account such that at the time of vaccination, the dogs are at or older than the oldest minimum vaccination age for the individual vaccines.
Consult product leaflets before administering products simultaneously.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
4.9 Amounts to be administered and administration route
Subcutaneous use.
Reconstitute immediately prior to use by the addition of the contents of one vial (1.0 ml) of the diluent provided or the vaccines of the Canigen range against rabies or leptospirosis as mentioned in section 4.8 (where these products are authorised). Sterile equipment should be used for administration.
Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.
Vaccination regime
Primary course vaccination:
A single injection should establish active immunity in dogs of 10 weeks of age or older. Where earlier protection is required a first dose may be given to puppies from 6 weeks of age, but because maternally derived passive antibody can interfere with the response to vaccination a final dose should be given 2 - 4 weeks later i.e. at 10 weeks of age or older.
Booster vaccination:
To maintain protection a single booster dose is recommended every three years.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No effects other than those in section 4.6
4.11 Withdrawal period(s) Not applicable.
5. IMMUNOLOGICAL PROPERTIES
ATCvet code: QI07AD02
The vaccine contains attenuated antigens to stimulate active immunity in dogs against canine distemper virus, canine parvovirus, canine contagious hepatitis caused by canine adenovirus 1 and respiratory disease caused by canine adenovirus type 2.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sorbitol
Gelatine
Pancreatic digest of casein
Disodium phosphate dihydrate Potassium dihydrogen phosphate Water for injections.
6.2 Incompatibilities
Do not mix with any other veterinary medicinal product except the solvent or the vaccines of the Canigen range listed in section 4.8.
6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 24 months.
Shelf life after reconstitution: 30 minutes.
6.4 Special precautions for storage
Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Protect from light.
Reconstituted vaccine: Store in a refrigerator at 2 °C – 8 °C with care being taken to avoid prolonged or repetitive exposure to high ambient temperature following withdrawal from the refrigerator prior to use.
6.5 Nature and composition of the immediate packaging
Clear, Glass Type I (Ph.Eur) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.
Cardboard or plastic boxes containing 10 or 50 single dose vials.
The solvent may be packed with the vaccine or separately. Not all pack sizes may be marketed.
6.6 Special precautions for disposal of unused veterinary medicinal product or waste material derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
MSD Animal Health UK Limited
Walton Manor, Walton
Milton Keynes
Buckinghamshire
MK7 7AJ
8. MARKETING AUTHORISATION NUMBER
Vm 01708/4620
9. DATE OF FIRST AUTHORISATION
21 April 2006
10. DATE OF REVISION OF THE TEXT
October 2022
Approved 25 October 2022
